Treatment of apoA-I:CIGB-258 at a molar ratio of 1:0.5 and 1:1 significantly prevented the CML-induced lipid accumulation as apparent by the significant 1.5-fold (p < 0.05) and 1.9-fold (p < 0.01) reduced ORO-stained area than the ORO stained quantified in the CML injected group. The gene discussed is APOA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.